CLL Updates and the Venetoclax Story With Matt Davids
Healthcare Unfiltered
Innovations in CLL Treatment
This chapter explores the groundbreaking combination therapy of venetoclax, acalbrutinib, and obinutuzumab for treating Chronic Lymphocytic Leukemia (CLL). The speakers discuss trial results, particularly focusing on undetectable minimal residual disease (MRD) rates and implications for future treatment standards. They also reflect on the evolution of CLL therapies, highlight the significance of MRD in treatment planning, and emphasize the need for further research to validate new approaches.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
